Medical Use
Portrazza is an EGFR antagonist approved for use with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not intended for the treatment of non-squamous NSCLC.
Recommended Dosage: The recommended dosage is 800 mg administered as an intravenous (IV) infusion over one hour on Days 1 and 8 of each 3-week cycle, prior to the infusion of gemcitabine and cisplatin. Continue Portrazza treatment until disease progression or unacceptable toxicity occurs.
For patients who have previously experienced a Grade 1/2 infusion-related reaction (IRR), pre-medicate with diphenhydramine hydrochloride (or equivalent) before all subsequent infusions of Portrazza.
For those who have experienced a second Grade 1/2 IRR, pre-medicate with acetaminophen (or equivalent), diphenhydramine hydrochloride (or equivalent), and dexamethasone (or equivalent) before each infusion of Portrazza.
Warning & Precautions
Monitoring and Safety Guidelines for Portrazza Treatment:
- -Electrolyte Monitoring: Closely monitor patients for serum electrolytes, including magnesium, calcium, and potassium, before each Portrazza infusion, during treatment, and for at least 8 weeks after the final dose.
- -Hypomagnesemia Risk: Hypomagnesemia may occur in patients treated with Necitumumab. Monitor for hypocalcemia, hypomagnesemia, and hypokalemia before each infusion, during treatment, and for at least 8 weeks post-treatment.
- -Thromboembolic Events: Venous and arterial thromboembolic events (VTE and ATE), some fatal, may occur with Portrazza in combination with cisplatin and gemcitabine. Discontinue treatment in cases of severe or life-threatening VTE or ATE.
- -Dermatologic Toxicities: Dermatologic toxicities such as acne, rash, dry skin, dermatitis acneiform, pruritus, generalized rash, maculopapular rash, and skin fissures may occur. Discontinue treatment for Grade 4 skin reactions or Grade 3 skin induration/fibrosis.
- -Infusion-Related Reactions (IRRs): Patients may experience IRRs of any severity. Monitor during and after the infusion for signs and symptoms of IRRs. Discontinue treatment for serious or life-threatening IRRs.
- -Fetal Harm Risk: Based on animal studies and its mechanism of action, Necitumumab can cause fetal harm when administered to pregnant women. Women of reproductive age should use effective contraception during treatment and for 3 months after the final dose.
Documentation Availability
Documents required to import Portrazza to India?
Portrazza can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing Portrazza from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for the trade name drug Portrazza®?
The generic name for Portrazza® is Necitumumab.
What is the Manufacturer’s Name of Portrazza®?
Portrazza® is manufactured by Eli Lilly and Company.
Is Portrazza® approved by the FDA?
Yes, Portrazza® was approved by the FDA on November 24, 2015.
What is the dosage and form of Portrazza® supplied?
Portrazza® is supplied as an injection: 800 mg/50 mL (16 mg/mL) solution in a single-dose vial for intravenous administration.
Where to Buy Portrazza® Injection in India?
You can buy Portrazza (necitumumab) 800 mg/50 mL (16 mg/mL) by Eli Lilly and Company online from https://rx4u.in/
What are the most common side effects of Portrazza®?
The most common side effects of Portrazza® are rash and hypomagnesemia.
How much does Portrazza cost in India?
The cost of Portrazza in India can vary. To procure this medication authentically, you can you can order the drug on https://rx4u.in/
What are the storage conditions of Portrazza®?
Store Portrazza vials in a refrigerator at 2-8°C (36-46°F). Keep the vials in the outer carton to protect them from light. Avoid freezing or shaking the vial.
Is it safe to buy Portrazza® online in India?
Yes, you can safely buy Portrazza injection online from the Rx4u who can help facilitate the import of Portrazza through legal channels.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
